Related Experiment Video
Updated: Jun 3, 2025
04:49
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
77
Low-dose methotrexate in Rheumatology: A reinvented drug.
Kushagra Gupta1, Vinod Ravindran2,3
1Joint and Autoimmune Clinic, Gupta Medical Centre, Hisar, Haryana, India.
The Journal of the Royal College of Physicians of Edinburgh
|January 10, 2025
Summary
Low-dose methotrexate (LD-MTX) is a safe anchor drug for rheumatological conditions, contrary to popular belief. Current evidence shows LD-MTX is not linked to liver or lung fibrosis, with serious side effects being rare.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Medicine
Background:
- Low-dose methotrexate (LD-MTX) is a cornerstone therapy for numerous rheumatological diseases.
- Misconceptions regarding LD-MTX safety persist, often stemming from data on high-dose chemotherapy regimens.
- A comprehensive review of current evidence is needed to clarify the safety profile of LD-MTX.
Purpose of the Study:
- To review and discuss the latest scientific data on the safety of long-term, low-dose methotrexate (LD-MTX) therapy.
- To address and debunk common myths and misconceptions surrounding LD-MTX use in rheumatology.
- To provide an evidence-based perspective on the safety and efficacy of LD-MTX for practitioners.
Main Methods:
- Systematic review and synthesis of recent clinical data and research findings on LD-MTX.
- Analysis of studies investigating potential adverse effects, including organ toxicity and malignancy risk.
- Evaluation of evidence regarding bone marrow suppression, infections, and pulmonary complications.
Main Results:
- Current evidence strongly supports the safety of LD-MTX, refuting associations with liver and lung fibrosis.
- Significant adverse events like bone marrow suppression and increased infection risk are infrequent with chronic LD-MTX use.
- Hypersensitivity pneumonitis is a rare acute toxicity, distinct from interstitial lung disease, and MTX may even offer protection against it. A slight concern for skin malignancy exists, but no other cancer associations were found.
Conclusions:
- Long-term low-dose methotrexate (LD-MTX) is demonstrably safe for treating rheumatological conditions.
- The academic and clinical communities should re-evaluate LD-MTX, recognizing its established safety and efficacy.
- LD-MTX should be viewed as a distinct and reliable therapeutic agent in modern rheumatology practice.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:29Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110
01:17Phase II Reactions: Methylation Reactions
131
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
131